Free Trial
NASDAQ:OTLK

Oncobiologics Q3 2025 Earnings Report

Oncobiologics logo
$1.34 -0.07 (-4.96%)
Closing price 04:00 PM Eastern
Extended Trading
$1.34 0.00 (0.00%)
As of 07:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Oncobiologics EPS Results

Actual EPS
-$0.44
Consensus EPS
-$0.42
Beat/Miss
Missed by -$0.02
One Year Ago EPS
N/A

Oncobiologics Revenue Results

Actual Revenue
$1.51 million
Expected Revenue
$1.66 million
Beat/Miss
Missed by -$157.00 thousand
YoY Revenue Growth
N/A

Oncobiologics Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
Thursday, August 14, 2025
Conference Call Time
12:00AM ET

Upcoming Earnings

Oncobiologics' Q4 2025 earnings is scheduled for Friday, December 26, 2025, with a conference call scheduled on Wednesday, December 24, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Oncobiologics Earnings Headlines

Outlook Therapeutics Provides Update on Type A Meeting with FDA
Buy alert: Move $1,000 before Tesla’s Optimus launch
Elon's $1,000,000,000,000 payday Elon Musk just made his biggest insider purchase of Tesla stock ever. He's preparing for a "mind blowing" new launch that could see Tesla move away from electric cars... and into a new market.tc pixel
Outlook Therapeutics Requests Type A Meeting with FDA
See More Oncobiologics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Oncobiologics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Oncobiologics and other key companies, straight to your email.

About Oncobiologics

Oncobiologics (NASDAQ:OTLK) is a clinical-stage biopharmaceutical company specializing in the development of biosimilar therapeutics for cancer and autoimmune diseases. Leveraging recombinant DNA technology and advanced formulation platforms, the company aims to create high-quality, cost-effective alternatives to originator biologic drugs. Oncobiologics’ research focus includes monoclonal antibodies and growth factors that support oncology treatment and immunomodulation.

Founded in 2005 and headquartered in Marlborough, Massachusetts, Oncobiologics maintains research facilities in the Greater Boston area and an integrated manufacturing site in Hyderabad, India, through its wholly owned subsidiary. This global footprint enables the company to conduct end-to-end process development and scale-up operations, optimizing both development timelines and production costs in major biopharmaceutical markets.

The company’s pipeline comprises multiple biosimilar candidates targeting established therapies in oncology and supportive care, with programs at various stages of preclinical and clinical development. Oncobiologics advances its portfolio through a disciplined clinical strategy and selective partnerships designed to streamline regulatory pathways. By focusing on broadening patient access to proven biologic medicines, the company seeks to address unmet needs in the United States, Europe and other global regions with its upcoming biosimilar products.

View Oncobiologics Profile

More Earnings Resources from MarketBeat